Date:11/17/2011

the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, disruptions arising from our management transition, expenses associated with our management transition, distraction of management and employees arising from our evaluation of strategic alternatives, including a potential sale of the company, expenses associated with our evaluation of strategic alternatives, uncertainty among customers, suppliers, employees and others regarding our management transition and our evaluation of strategic alternatives, prolonged impairment of sales from changes in our sales organization, revenue shortfalls arising from customer transitions to new products, unpredictability in large customer orders, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, reduced margins resulting from a shift in revenue towards services, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict. SERACARE LIFE SCIENCES, INC.STATEMENTS OF OPERATIONS — UNAUDITEDFor the Three Months EndedFor the Twelve Months EndedSeptember 30,September 30,2011201020112010Revenue

$
,990,229$
3,296,546$
43,484,232$
50,380,140Cost of revenue

6,707,9728,093,74526,741,33229,594,419Gross profit

4,282,2575,202,80116,742,90020,785,721Research and development expense

427,468234,7681,276,944777,068Selling
'/>"/>

SOURCE SeraCare Life Sciences, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. SeraCare Life Sciences Secures $20 Million Credit Facilities
2. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 2011
3. SeraCare Reports First Quarter Fiscal Year 2011 Results
4. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
5. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors
6. SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
7. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
8. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
9. Par Pharmaceutical Reports Second Quarter 2008 Results
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. Pharmos Corporation Reports 2008 Second Quarter Results